Better Scenario For TLD-1433 In NSCLC... Would be a win-win for Lumeda (& de facto/partnered TLT) to insert TLD-1433 into the planned PDT + immunotherapy Ph 1 AND replace the 12 patient Photofrin study with TLD-1433. Lumeda would be significantly selling themselves short by using the less promising Photofrin imo. There's no better way to highlight your technology than by using the most promising (pre-clinically & clinically) photodynamic compound on the market today in TLD-1433.
Together, Lumeda's DIGILUM IO-PDT system & TLD-1433 would be used as a "single" adjuvant intraoperative therapy. And using TLD-1433 PDT in the combo trial (PDT + Immunotherapy) could prove our compound is a preferred "stand-alone" option...with no added benefit demonstrated by adding on immunotherapy/immune checkpoint inhibition. Using our compound "only in the combo trial" ignores the potential of TLD-1433 PDT as being (INDEPENDENTLY) the new SOC for this NSCLC indication.
Hope the above can happen soon...JMO.